P/E ratio for Gilead Sciences (GILD)

P/E ratio history for Gilead Sciences from 2001 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	30.5	54.52%	🇺🇸 USA
Pfizer PFE	21.2	7.24%	🇺🇸 USA
AbbVie ABBV	127	544.98%	🇺🇸 USA
Eli Lilly LLY	40.3	104.38%	🇺🇸 USA
Amgen AMGN	26.3	33.52%	🇺🇸 USA
Biogen BIIB	23.2	17.82%	🇺🇸 USA
Illumina ILMN	37.7	90.81%	🇺🇸 USA
Vertex Pharmaceuticals VRTX	30.5	54.78%	🇺🇸 USA
Merck MRK	40.5	105.35%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.